Skip to main content

Auto-SCT for AML in second remission: CALGB study 9620.

Publication ,  Journal Article
Linker, CA; Owzar, K; Powell, B; Hurd, D; Damon, LE; Archer, LE; Larson, RA; Cancer and Leukemia Group B,
Published in: Bone Marrow Transplant
September 2009

We studied the feasibility and efficacy of a two-step approach to Auto-SCT for patients with AML in second remission. Step 1 consisted of consolidation chemotherapy using cytarabine 2000 mg/m(2) i.v. every 12 h for 4 days plus etoposide 40 mg/kg total dose by continuous i.v. infusion over the same 4 days. PBSC were collected after G-CSF stimulation during recovery from this chemotherapy. Step 2, auto-SCT, used a preparative regimen of oral BU 16 mg/kg over 4 days followed by etoposide 60 mg/kg i.v. Of the 50 patients entered on Step 1, two died from treatment complications, and seven failed to proceed to transplantation. A median CD34+ cell dose of 5.9 x 10(6)/kg was collected in a median of three collections. With a median follow-up of 8.2 years, 5-year disease-free survival (DFS) is 28%. The most important prognostic factor was cytogenetics, with acute promyelocytic leukemia (APL) patients having a 5-year DFS of 67% compared with 16% for others. We conclude that this two-step approach to autologous transplantation produces good CD34+ mobilization and that this approach has cured some patients. Results in patients with APL are especially promising.

Duke Scholars

Published In

Bone Marrow Transplant

DOI

EISSN

1476-5365

Publication Date

September 2009

Volume

44

Issue

6

Start / End Page

353 / 359

Location

England

Related Subject Headings

  • Young Adult
  • Treatment Refusal
  • Treatment Outcome
  • Transplantation, Autologous
  • Remission Induction
  • Peripheral Blood Stem Cell Transplantation
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Kaplan-Meier Estimate
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Linker, C. A., Owzar, K., Powell, B., Hurd, D., Damon, L. E., Archer, L. E., … Cancer and Leukemia Group B, . (2009). Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant, 44(6), 353–359. https://doi.org/10.1038/bmt.2009.36
Linker, C. A., K. Owzar, B. Powell, D. Hurd, L. E. Damon, L. E. Archer, R. A. Larson, and R. A. Cancer and Leukemia Group B. “Auto-SCT for AML in second remission: CALGB study 9620.Bone Marrow Transplant 44, no. 6 (September 2009): 353–59. https://doi.org/10.1038/bmt.2009.36.
Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, et al. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant. 2009 Sep;44(6):353–9.
Linker, C. A., et al. “Auto-SCT for AML in second remission: CALGB study 9620.Bone Marrow Transplant, vol. 44, no. 6, Sept. 2009, pp. 353–59. Pubmed, doi:10.1038/bmt.2009.36.
Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, Larson RA, Cancer and Leukemia Group B. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant. 2009 Sep;44(6):353–359.

Published In

Bone Marrow Transplant

DOI

EISSN

1476-5365

Publication Date

September 2009

Volume

44

Issue

6

Start / End Page

353 / 359

Location

England

Related Subject Headings

  • Young Adult
  • Treatment Refusal
  • Treatment Outcome
  • Transplantation, Autologous
  • Remission Induction
  • Peripheral Blood Stem Cell Transplantation
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Kaplan-Meier Estimate